Drugs / mCTLs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02510404 | Apr 2014 → May 2019 | — | Catherine Bollard | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mCTLs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02510404 ↗ |
| Modality | Cell therapy | “third-party multivirus-specific cytotoxic T lymphocytes (mCTL)” NCT02510404 ↗ |
| Route | Other | “infused mCTLs” NCT02510404 ↗ |